Sonoma Pharmaceuticals, Inc. (SNOA)
NASDAQ: SNOA · Real-Time Price · USD
1.040
-0.070 (-6.31%)
At close: Apr 28, 2026, 4:00 PM EDT
1.038
-0.002 (-0.19%)
Pre-market: Apr 29, 2026, 5:32 AM EDT
Sonoma Pharmaceuticals Revenue
Sonoma Pharmaceuticals had revenue of $4.35M in the quarter ending December 31, 2025, with 22.03% growth. This brings the company's revenue in the last twelve months to $17.72M, up 26.83% year-over-year. In the fiscal year ending March 31, 2025, Sonoma Pharmaceuticals had annual revenue of $14.29M with 12.19% growth.
Revenue (ttm)
$17.72M
Revenue Growth
+26.83%
P/S Ratio
0.28
Revenue / Employee
$2,215,250
Employees
8
Market Cap
4.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 14.29M | 1.55M | 12.19% |
| Mar 31, 2024 | 12.74M | -537.00K | -4.05% |
| Mar 31, 2023 | 13.27M | 644.00K | 5.10% |
| Mar 31, 2022 | 12.63M | -6.00M | -32.21% |
| Mar 31, 2021 | 18.63M | 701.00K | 3.91% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Biofrontera | 41.71M |
| Sunshine Biopharma | 36.31M |
| cbdMD | 19.09M |
| RedHill Biopharma | 9.55M |
| InMed Pharmaceuticals | 4.51M |
| China SXT Pharmaceuticals | 1.54M |
| Akanda | 836.66K |
| Gelteq | 270.85K |
SNOA News
- 4 days ago - Sonoma Pharmaceuticals Announces Pricing of $4 Million Public Offering - Accesswire
- 5 weeks ago - Sonoma Pharmaceuticals Announces U.S. Retail Launch of Advanced Burn Relief Hydrogel in CVS and Walmart - Accesswire
- 5 weeks ago - Sonoma Pharmaceuticals Announces Launch of New Dermatology Product Line under Person & Covey's Aquanil Brand for Sensitive Skin - Accesswire
- 2 months ago - Sonoma Pharmaceuticals Reports Third Fiscal Quarter 2026 Financial Results - Accesswire
- 3 months ago - Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development - Accesswire
- 5 months ago - National Rosacea Society Awards Seal of Acceptance to Sonoma Pharmaceuticals for Reliefacyn Advanced - Accesswire
- 6 months ago - Sonoma Pharmaceuticals to Exhibit at MEDICA 2025 in Düsseldorf - Accesswire
- 6 months ago - Sonoma Pharmaceuticals Reports Second Fiscal Quarter 2026 Financial Results - Accesswire